AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$ABT

MCCOY JOHN A. JR. sold $3K of ABT

MCCOY JOHN A. JR. (VICE PRESIDENT AND CONTROLLER) sold 27 shares of ABBOTT LABORATORIES (ABT) at $109.54 on 2026-09-02.

Original reporting
SEC EDGAR · MCCOY JOHN A. JR.
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABT
Neutral
high confidence
Mentioned
$ABT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The transaction is a routine sale with minimal market relevance.

02

Market read

Low relevance; no expected price movement.

03

What to watch

Potential upcoming earnings or corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing for Abbott Laboratories insider transaction.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Form 4 shows VP John McCoy sold 27 shares for $2,958, reducing his stake to 24,549 shares.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is trivial relative to market cap and insider ownership.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal concerns, but evidence is insufficient.

Key entities

  • company
    Abbott Laboratories

    US healthcare company (ticker ABT).

  • person
    John A. McCoy Jr.

    Vice President and Controller, insider.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABT insider trading history →

Related articles

OCT 7
$ABTLow

Whistleblowers Help DOJ Achieve $385 Million Settlement with Abbott Laboratories for Contaminated Infant Formula Sold to Government Programs – RACmonitor

Abbott Laboratories agreed to a $385M settlement with the DOJ for alleged false claims related to contaminated infant formula sold to government programs. The settlement resolves claims that Abbott failed to meet manufacturing standards at its Michigan and Arizona facilities. The company did not admit liability. The settlement includes $348.7M to the federal government and $36.3M to state Medicaid programs. Three whistleblowers will receive $69M for their role in exposing the allegations.

medlearn.com2 min
OCT 7
$ABTLow

Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything

Abbott Laboratories agreed to a $385M settlement to resolve a False Claims Act lawsuit over alleged contamination at its Sturgis, Michigan, and Casa Grande, Arizona, plants. The DOJ and state AGs filed the suit, citing poor conditions and alleged concealment of contamination tests. Abbott denied liability. The 2022 recall caused widespread formula shortages. Whistleblowers will receive $69M.

lawnews.co.uk2 min
OCT 6
MedAI 8/10

Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative?

Abbott Laboratories received FDA approval for upgrades to its CardioMEMS HF System and launched SimpleScreen CRC, a blood-based colorectal cancer screening test. These updates extend Abbott's reach in heart failure monitoring and early cancer detection. Analysts expect 8.8% yearly revenue growth and profit margins rising to 16.0% by 2029, with a consensus earnings forecast of $9.6b by 2029.

simplywall.st3 min